[Form 4] Cardiff Oncology, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Form 4 filing overview

On June 23, 2025, GlycoMimetics, Inc. (GLYC) disclosed that director Jonathan Violin received a stock option covering 9,023 ordinary shares at an exercise price of $15.30 per share. The award vests in full on the earlier of June 23, 2026 or the company’s next annual shareholder meeting, provided he remains in service, and expires on June 23, 2035. The option is held directly by Violin; no open-market purchases or sales of common stock were reported, and Table I shows no changes in non-derivative share ownership.

The filing represents a routine equity incentive grant to a non-employee director. While it increases Violin’s long-term exposure to the company’s equity, it does not, by itself, indicate a change in insider sentiment or the firm’s financial outlook.

Insights

Securities Analyst

TL;DR: Routine director option grant; negligible near-term market impact.

The Form 4 documents a standard non-employee director incentive—9,023 options at $15.30, vesting within one year, expiring in 2035. No common-stock transactions occurred, so the company’s share float and insider ownership of outstanding shares remain unchanged. Such grants are customary for governance and retention and typically do not affect valuation metrics or trading dynamics. Investors should view the disclosure as administrative rather than a signal of bullish or bearish insider activity.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mohindru Mani

(Last) (First) (Middle)

C/O CARDIFF ONCOLOGY, INC.

11055 FLINTKOTE AVENUE

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cardiff Oncology, Inc. [ CRDF ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$3.16	06/26/2025		A		40,565		06/26/2026	06/26/2035	Common Stock	40,565	$0	168,766	D

Explanation of Responses:

	/s/ Mani Mohindru	06/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did GlycoMimetics (GLYC) report in the latest Form 4?

A grant of a stock option to director Jonathan Violin for 9,023 shares.

How many shares are covered by Jonathan Violin’s new option?

The option covers 9,023 ordinary shares.

What is the exercise price of the option granted on June 23, 2025?

The exercise price is $15.30 per share.

When will the option granted to Jonathan Violin vest?

It vests on the earlier of June 23, 2026 or the next annual shareholder meeting.

Did the Form 4 show any purchase or sale of GLYC common stock?

No; only an option grant was reported, with no changes to common-stock holdings.